1644498-53-2
Chemical Structure
BI-9774
- CAS No.: 1644498-53-2
- Formula:C26H25ClN4O5S
- Molecular Weight:541.02
IUPAC Name: ((4'-(6-chloro-2-(((3R,3aR,6R,6aR)-6-hydroxyhexahydrofuro[3,2-b]furan-3-yl)oxy)-1H-imidazo[4,5-b]pyridin-5-yl)-[1,1'-biphenyl]-4-yl)imino)dimethyl-l6-sulfanone
InChIKey: JUSYNSOYFIIJQX-LUGTWXOSSA-N
SMILES: O(C1=NC=2C(N1)=CC(Cl)=C(N2)C3=CC=C(C=C3)C4=CC=C(N=S(C)(C)=O)C=C4)[C@H]5[C@@]6([C@](OC5)([C@H](O)CO6)[H])[H]
Biological Activity: BI-9774 is a potent, selective, and orally active AMPK activator, with EC50 values of 20.0 nM and 63.1 nM against human AMPK α1β1γ1 and AMPK α1β2γ1, respectively. BI-9774 binds to the allosteric drug and metabolite (ADaM) site and induces ACC Ser79 phosphorylation in HepG2 cells, with an EC50 of 83.2 nM. BI-9774 can be used in studies related to AMPK signaling, multiple sclerosis, and non-alcoholic fatty liver disease[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BI-9774 | BI-9774 is a potent, selective, and orally active AMPK activator, with EC50 values of 20.0 nM and 63.1 nM against human AMPK α1β1γ1 and AMPK α1β2γ1, respectively. BI-9774 binds to the allosteric drug and metabolite (ADaM) site and induces ACC Ser79 phosphorylation in HepG2 cells, with an EC50 of 83.2 nM. BI-9774 can be used in studies related to AMPK signaling, multiple sclerosis, and non-alcoholic fatty liver disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Himmelsbach F, et al. NEW AZABENZIMIDAZOLE DERIVATIVES. WO 2015/007669 A1. 2015-01-22.
- [2]. Bustraan S, et al. AMP-activated protein kinase activation suppresses leptin expression independently of adipogenesis in primary murine adipocytes. The Biochemical journal. 2024 Mar 06;481(5):345-362.
- [3]. Papadopoulou G, et al. Adenosine 2A receptor-dependent activation of AMPK represses T17 cell pathogenicity through epigenetic and metabolic reprogramming. Science signaling. 2025 Sep 23;18(905):eadr3177.
- [4]. Mather KM, et al. Direct β1/β2 AMPK activation reduces liver steatosis but not fibrosis in a mouse model of non-alcoholic steatohepatitis. bioRxiv [Preprint]. 2024 Jun 2:2024.05.30.596624.
Keywords
